Akeso Past Earnings Performance
Past criteria checks 4/6
Akeso has been growing earnings at an average annual rate of 38.1%, while the Biotechs industry saw earnings growing at 14.7% annually. Revenues have been growing at an average rate of 86.8% per year. Akeso's return on equity is 43%, and it has net margins of 44.8%.
Key information
38.1%
Earnings growth rate
63.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 86.8% |
| Return on equity | 43.0% |
| Net Margin | 44.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Akeso makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 4,526 | 2,028 | 1,090 | 1,254 |
| 30 Sep 23 | 4,439 | 2,008 | 1,071 | 1,278 |
| 30 Jun 23 | 4,351 | 1,987 | 1,052 | 1,302 |
| 31 Mar 23 | 2,595 | 409 | 902 | 1,313 |
| 31 Dec 22 | 838 | -1,168 | 752 | 1,323 |
| 30 Sep 22 | 549 | -1,224 | 672 | 1,239 |
| 30 Jun 22 | 260 | -1,280 | 592 | 1,155 |
| 31 Mar 22 | 243 | -1,178 | 508 | 1,139 |
| 31 Dec 21 | 226 | -1,075 | 423 | 1,123 |
| 30 Sep 21 | 177 | -1,002 | 324 | 1,107 |
| 30 Jun 21 | 129 | -929 | 226 | 1,091 |
| 31 Mar 21 | 64 | -983 | 240 | 930 |
| 31 Dec 20 | 0 | -1,036 | 253 | 769 |
| 30 Sep 20 | 35 | -870 | 197 | 597 |
| 30 Jun 20 | 71 | -703 | 141 | 426 |
| 31 Mar 20 | 71 | -492 | 98 | 367 |
| 31 Dec 19 | 71 | -282 | 55 | 308 |
| 31 Dec 18 | 3 | -142 | 20 | 161 |
Quality Earnings: AKES.F has high quality earnings.
Growing Profit Margin: AKES.F became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AKES.F has become profitable over the past 5 years, growing earnings by 38.1% per year.
Accelerating Growth: AKES.F has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: AKES.F has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: AKES.F's Return on Equity (43%) is considered outstanding.